Clinical trials: Pancreatic Metastasis
Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified
A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab
This is an open-label, phase 1/2, multiple-indication platform study to explore safety, potential predictive immune-related biomarkers, and early efficacy (as measured by objective response rate [ORR; Cohorts 1,2, 4,and 5] and…
- Conditions
- Anal Cancer Metastatic, Squamous Cell Carcinoma of the Anus Stage Unspecified, Pancreatic Cancer Metastatic, Unresectable Pancreatic Carcinoma
- Trial name
- GOBLET (NCT07280377)
- Testing
- Pelareorep, Atezolizumab, Gemcitabine and nab-paclitaxel
- Where
- 15 sites in Germany
- Volunteers
- 122 people
- Sponsor
- Oncolytics Biotech
Pancreatic Cancer
Genes as Predictors of Response to Gemcitabine, Docetaxel, and Capecitabine (GTX) in Metastatic or Unresectable Pancreatic Cancer.
This is a study for patients with advanced pancreatic cancer, using the drugs gemcitabine, docetaxel and capecitabine. Gemcitabine is a drug that has been approved by the FDA.
- Trial name
- NCT00159471
- Testing
- capecitabine, gemcitabine, docetaxel
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Southern California
Gastrointestinal Neoplasms
Safety Study of Combining Ultrasound Microbubbles and Chemotherapy to Treat Malignant Neoplasms of Digestive System
Ultrasonic sonoporation can increase the release of chemotherapeutics, thus increasing the therapeutic effects. The main purpose is to identify the safety of combining ultrasonic microbubbles and chemotherapeutics to treat…
- Trial name
- NCT02233205
- Testing
- ultrasonic microbubbles, platinum and gemcitabine
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University Cancer Hospital & Institute
Anal Cancer, Colorectal Cancer
Interleukin-12 in Treating Patients With Cancer in the Abdomen
RATIONALE: Interleukin-12 may kill tumor cells by stimulating a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-12 in treating patients with cancer in the abdomen.
- Conditions
- Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer
- Trial name
- NCT00003046
- Testing
- Recombinant Interleukin-12
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Pancreatic Cancer
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Phase I study of lapatinib and gemcitabine for patients with metastatic pancreaticobiliary cancer.
- Trial name
- NCT00447122
- Testing
- Gemcitabine 1000mg/m2 30 minutes, Lapatinib 1000mg/d, Lapatinib 1500mg/d
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Brown University
Pancreatic Cancer
A Study of Capecitabine (Xeloda) in Participants With Locally Advanced or Metastatic Pancreatic Cancer
This study will evaluate the efficacy and safety of oral capecitabine plus intravenous (IV) gemcitabine in participants with locally advanced or metastatic pancreatic cancer.
- Trial name
- NCT02565641
- Testing
- Capecitabine, Gemcitabine
- Where
- 7 sites in South Korea
- Volunteers
- 63 people
- Sponsor
- Hoffmann-La Roche
Adenocarcinoma
AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer
The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas.
- Trial name
- NCT01182246
- Testing
- AXP107-11
- Where
- 2 sites in Sweden
- Volunteers
- 44 people
- Sponsor
- Axcentua Pharmaceuticals AB
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Neuroendocrine Tumors, Carcinoid Tumors
Study of Pasireotide Long Acting Release (LAR) in Patients With Metastatic Neuroendocrine Tumors (NETs)
The goal of this clinical research study is to learn if the study drug, Pasireotide LAR can shrink or slow the growth of Metastatic Neuroendocrine Carcinomas. The safety of this drug will also be studied.
- Trial name
- NCT01253161
- Testing
- Pasireotide Long Acting Release (LAR)
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Metastatic Pancreatic Cancer
Combination Chemotherapy for 1st Line Treatment of Advanced or Metastatic Pancreatic Cancer
The purpose of this study is to find out if giving patients bevacizumab along with the chemotherapy drugs oxaliplatin and gemcitabine will improve overall survival.
- Trial name
- NCT00222469
- Testing
- bevacizumab, gemcitabine, oxaliplatin
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- University of Oklahoma
Pancreatic Cancer Non-resectable, Pancreatic Cancer Metastatic
Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic…
- Trial name
- CSPAC-48 (NCT06916975)
- Testing
- Adebrelimab, AG
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Jin Xu
Pancreatic Cancer
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
This is a study of a Multicenter, Randomized, Double-Blind, Phase III Study of IBI343 Monotherapy Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Participants with Claudin (CLDN) 18.2-Positive, Locally…
- Trial name
- NCT07066098
- Testing
- IBI343
- Where
- China
- Volunteers
- 201 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Pancreatic Neoplasms
GEMOX: Oxaliplatin in Pancreatic Cancer
Primary objective: To evaluate overall response rate (based on RECIST criterion) Secondary objective: To evaluate time to progression, clinical benefit, quality of life and safety
- Trial name
- NCT00261092
- Testing
- Oxaliplatin
- Where
- South Korea
- Volunteers
- 48 people
- Sponsor
- Sanofi
Peritoneal Carcinomatosis, Pancreas Neoplasm
Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases
Combined chemotherapy consisting of endovenous Nabpaclitaxel-Gemcitabine and Nabpaclitaxel-PIPAC may be a promising treatment for patients affected by pancreatic cancer PM who are in need of curative options.
- Trial name
- Nab-PIPAC (NCT05371223)
- Testing
- Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Cancer
Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients
This study aims to determine if web-based eHealth delivery of pre-test and/or post-test counseling in cancer patients and/or those at risk for cancer can provide equal or improved cognitive and affective outcomes when compared to…
- Trial name
- eReach (NCT04353973)
- Testing
- Pre-Test Intervention, Standard of Care, Post-Test Intervention
- Where
- United States
- Volunteers
- 256 people, healthy volunteers welcome
- Sponsor
- Abramson Cancer Center at Penn Medicine
Metastatic Adenocarcinoma of the Pancreas
Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Participants Not Previously Treated for Metastatic Adenocarcinoma of the Pancreas
This study is to assess the anti-tumour activity, safety and tolerability of irinotecan liposome injection (S095013) in combination with oxaliplatin, 5-Fluorouracil (5-FU) and levoisomer form of leucovorin (LLV).
- Trial name
- NCT06225999
- Testing
- Irinotecan liposome injection (S095013), Oxaliplatin, LLV (levoisomer form of leucovorin)
- Where
- 14 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Institut de Recherches Internationales Servier
Metastatic Pancreatic Cancer, Pancreatic Cancer
Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer
The primary objective of this study was to determine the progression free survival in patients with metastatic pancreatic cancer and in patients with locally advanced unresectable non-metastatic pancreatic cancer treated with a…
- Trial name
- FOLFIRINOX (NCT01523457)
- Testing
- Folfirinox
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Yale University
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Advanced/Metastatic Solid Tumors
Study of NMS-03305293 in Pts with Selected Advanced/Metastatic Solid Tumors
Phase I, first-in-human, open-label, multicenter, dose-escalation and dose expansion study with the aim of exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP inhibitor) as single agent in…
- Trial name
- NCT04182516
- Testing
- NMS-03305293
- Where
- 10 sites in United States, Bulgaria and 3 more
- Volunteers
- 52 people
- Sponsor
- Nerviano Medical Sciences
Metastatic Pancreatic Cancer
RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer
This will be a Phase 1b/2a multicenter 2-stage study. Phase 1 will be conducted as a dose-finding, open-label study of oral RX-3117 administered in combination with Abraxane® to subjects with metastatic pancreatic cancer.
- Trial name
- NCT03189914
- Testing
- RX-3117
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- Processa Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.